Chemoradiotherapy versus surgery followed by postoperative radiotherapy in tonsil cancer: Korean Radiation Oncology Group (KROG) study by 湲덇린李� et al.
RESEARCH ARTICLE Open Access
Chemoradiotherapy versus surgery
followed by postoperative radiotherapy in
tonsil cancer: Korean Radiation Oncology
Group (KROG) study
Sanghyuk Song1, Hong-Gyun Wu2*, Chang Geol Lee3, Ki Chang Keum3, Mi Sun Kim3, Yong Chan Ahn4,
Dongryul Oh4, Hyo Jung Park4, Sang-Wook Lee5, Geumju Park5, Sung Ho Moon6, Kwan Ho Cho6, Yeon-Sil Kim7,
Yongkyun Won7, Young-Taek Oh8, Won-Taek Kim9 and Jae-Uk Jeong10
Abstract
Background: Treatment of tonsil cancer, a subset of oropahryngeal cancer, varies between surgery and radiotherapy.
Well-designed studies in tonsil cancer have been rare and it is still controversial which treatment is optimal. This study
aimed to assess the outcome and failure patterns in tonsil cancer patients treated with either approaches.
Methods: We retrospectively reviewed medical records of 586 patients with tonsil cancer, treated between 1998 and
2010 at 16 hospitals in Korea. Two hundred and one patients received radiotherapy and chemotherapy (CRT), while
385 patients received surgery followed by radiotherapy and/or chemotherapy (SRT). Compared with the SRT group,
patients receiving CRT were older, with more advanced T stage and received higher radiotherapy dose given by
intensity modulation techniques. Overall survival (OS), disease-free survival (DFS), locoregional recurrence-free
survival (LRRFS), distant metastasis-free survival (DMFS), and clinicopathologic factors were analyzed.
Results: At follow-up, the 5-year OS, DFS, LRRFS and DMFS rates in the CRT group were 82, 78, 89, and 94%,
respectively, and in the SRT group were 81, 73, 87, and 89%, respectively. Old age, current smoking, poor performance
status, advanced T stage, nodal involvement, and induction chemotherapy were associated with poor OS. Induction
chemotherapy had a negative prognostic impact on OS in both treatment groups (p = 0.001 and p = 0.033 in the CRT
and SRT groups, respectively).
Conclusions: In our multicenter, retrospective study of tonsil cancer patients, the combined use of radiotherapy and
chemotherapy resulted in comparable oncologic outcome to surgery followed by postoperative radiotherapy, despite
higher-risk patients having been treated with the definitive radiotherapy. Induction chemotherapy approaches combined
with either surgery or definitive radiotherapy were associated with unfavorable outcomes.
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Background
The tonsils, a subsite of the oropharynx, are the most
common site of oropharyngeal neoplasm [1]. The inci-
dence of tonsil cancer is increasing [2, 3]. Odynophagia,
dysphagia, otalgia and asymptomatic mass is common
presentations. Histologically, squamous cell carcinoma is
most commonly observed in tonsil cancer. Regional
nodal metastases are frequent in more than half of
patients, while contralateral nodal diseases are found in
more than one fifth of patients with tonsil cancer [4].
Management of tonsil cancer is limited to either surgery
or radiotherapy, yet there is a scarcity of randomized
prospective trials comparing these treatment options.
However, several retrospective studies published similar
oncologic outcomes with both modalities [5–7]. There-
fore, current guidelines recommend both strategies based
on such findings [8].
In recent decades, breakthroughs in the field have
included the introduction of chemotherapy, resulting in
improved survival rates after definitive radiotherapy and
postoperative radiotherapy [9, 10]. Furthermore, ran-
domized clinical trial data showed that more than half of
oropharyngeal cancers were human papillomavirus (HPV)
positive and responded well to definitive radiotherapy
[11]. The incidence of HPV positive tumors is continu-
ously increasing [12]. In the era of chemotherapy and
endemic HPV, comparisons of the efficacy between treat-
ment modalities is still controversial. In the present study,
we conducted a large-scale retrospective multicenter study
to evaluate the outcome of chemoradiotherapy and
surgery followed by postoperative radiotherapy in tonsil
cancer patients.
Methods
A total of 620 tonsil cancer patients who were treated
with radiotherapy between 1998 and 2010 were identi-
fied in 16 institutions in Korea. Of these, we analyzed
data from 586 patients who were treated with definitive
radiotherapy with chemotherapy (CRT; 201 patients) or
surgery followed by radiotherapy and/or chemotherapy
(SRT; 385 patients). All institutional review boards of
participating hospitals approved the collection of these
data. The need for consent had been waived by the insti-
tutional review boards. Patient demographics, perform-
ance status, smoking history, imaging study, stage,
pathology, type of surgery, radio- and chemotherapeutic
information, and follow-up results were compiled.
The median age at diagnosis was 56 (range, 26–89) and
patients were predominantly male (89%). The perform-
ance status of most patients was Eastern Cooperative
Oncology Group (ECOG) grade 0–1 (94%). More than
half of the patients (52%) had a history of smoking. Com-
puted tomography (CT) scans of the neck were performed
at diagnosis in 91% of individuals; positron emission
tomography (PET) or CT scans were taken in 69% of
patients, while magnetic resonance imaging of the
oropharynx and neck was performed in 48%.
Patient characteristics according to the two treatment
groups are summarized in Table 1. Younger patients and
those with early T stage were more likely to receive
surgery (p = 0.041 and 0.002, respectively). Unknown
histologic differentiation was less frequent in the SRT
group. Chemotherapy and intensity modulated radio-
therapy (IMRT) were more commonly used in the CRT
group (p < 0.001 and 0.014, respectively). Radiotherapy
dose was also higher in the CRT group than in those
receiving SRT (p < 0.001).
Overall survival (OS) was defined as the time from the
date of treatment initiation to either death or last
follow-up. Disease-free survival (DFS) was defined as the
time from treatment initiation to recurrence, death, or
last follow-up. Locoregional recurrence-free survival
(LRRFS) and distant metastasis-free survival (DMFS)
were defined as the time from treatment initiation to
locoregional/distant recurrence or last follow-up,
respectively. Univariate and multivariate analyses were
performed using the log rank test and Cox-proportional
hazard regression model, respectively.
Results
With a median follow-up duration of 54 months (range,
2–176 months), 67 (11%) patients demonstrated locore-
gional recurrence, while 50 (9%) patients failed with
distant metastases. The 5-year OS, DFS, LRRFS, and
DMFS rates of the cohort as a whole were 81, 75, 87,
and 91%, respectively. When the data from the CRT and
SRT groups were analyzed independently, no significant
differences were observed between the two groups. The
5-year OS rates were 82 and 81% (p = 0.698) in the CRT
and SRT groups, respectively; DFS, 78 and 73%
(p = 0.612); LRRFS, 89 and 87% (p = 0.695); and DMFS,
94 and 89% (p = 0.157). The survival curves of each
group are plotted in Fig. 1.
Older age, current smoking, advanced T and N stage,
and induction chemotherapy treatment were associated
with poor OS in the univariate analysis (Table 2).
Furthermore, patients undergoing induction chemother-
apy showed inferior survival in both treatment groups
(Fig. 2); the 5-year OS rates of patients treated with and
without induction chemotherapy were 71 and 83%,
respectively (p < 0.001). This significant finding was also
observed when the treatment groups were analyzed inde-
pendently; in the CRT group, the 5-year OS rates of
patients with or without induction chemotherapy were 70
and 84% (p = 0.001), respectively, and 72% vs 82% in the
SRT group (p = 0.033).
The multivariate analysis (Table 3) also indicated that
induction chemotherapy was a risk factor for poor OS
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Table 1 Patient Characteristics
Characteristic Number of patients (%)
All (n = 586) CRT (n = 201) SRT (n = 385) p-value
Sex 0.913
Male 523 (89) 179 (89) 344 (89)
Female 63 (11) 22 (11) 41 (11)
Age (years) 0.041
< 60 395 (67) 125 (62) 270 (70)
≥ 60 189 (32) 76 (38) 113 (29)
Unknown 2 (0) 0 (0) 2 (1)
Smoker 0.673
Never smoker 232 (40) 73 (36) 159 (41)
Ex-smoker a 98 (17) 32 (16) 66 (17)
Current smoker 206 (35) 73 (36) 133 (35)
Unknown 50 (8) 23 (11) 27 (7)
Performance 0.351
ECOG 0 197 (34) 74 (37) 123 (32)
ECOG 1 351 (60) 117 (58) 234 (61)
ECOG 2 21 (3) 5 (2) 16 (4)
Unknown 17 (3) 5 (2) 12 (3)
PET/CT 0.072
No 182 (31) 72 (36) 110 (29)
Yes 404 (69) 129 (64) 275 (71)
Differentiation <0.001
WD 62 (11) 15 (7) 47 (12)
MD 297 (51) 73 (36) 224 (58)
PD 129 (22) 37 (18) 92 (24)
UD 16 (3) 11 (5) 5 (1)
Unknown 82 (14) 65 (32) 17 (4)
T stage 0.002
T1 134 (23) 31 (15) 103 (27)
T2 292 (50) 101 (50) 191 (50)
T3 74 (13) 30 (15) 44 (11)
T4a 73 (12) 30 (15) 43 (11)
T4b 13 (2) 9 (4) 4 (1)
N stage 0.779
N0 73 (12) 20 (10) 53 (14)
N1 79 (13) 28 (14) 51 (13)
N2a 45 (8) 16 (8) 29 (8)
N2b 307 (52) 105 (52) 202 (52)
N2c 60 (10) 23 (11) 37 (10)
N3 22 (4) 9 (4) 13 (3)
Stage 0.092
I 8 (1) 2 (1) 6 (2)
II 42 (7) 23 (11) 37 (10)
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Table 1 Patient Characteristics (Continued)
III 82 (14) 29 (14) 53 (14)
IVA 419 (72) 143 (71) 276 (72)
IVB 35 (6) 18 (9) 17 (4)
Chemotherapy <0.001
Induction 61 (10) 33 (16) 28 (7)
Concurrent 244 (42) 167 (83) 77 (20)
Adjuvant 13 (2) 1 (1) 12 (3)
No 268 (46) 0 (0) 268 (70)
Radiotherapy technique 0.014
3D–CRT 391 (67) 121 (60) 270 (70)
IMRT 194 (33) 80 (40) 114 (30)
Unknown 1 (0) 0 (0) 1 (0)
Total dose of radiotherapy Median 66 Median 70 Median 63 <0.001
(Gy) (range, 25.2–76) (range, 59.4–76) (range, 25.2–72.6)
Abbreviations: CRT radiotherapy with chemotherapy, SRT surgery followed by radiotherapy, ECOG Eastern Cooperative Oncology Group, PET/CT positron emission
tomography/computed tomography, WD well differentiated, MD moderate differentiation, PD poor differentiation, UD undifferentiated, 3D–CRT three-dimensional
conformal radiotherapy, IMRT intensity modulated radiotherapy
aAn adult who has smoked at least 100 cigarettes in his or her lifetime but who had quit smoking at the time of diagnosis
Fig. 1 Overall survival, disease-free survival, locoregional recurrence-free survival, and distant metastasis-free survival according to treatment group
Song et al. BMC Cancer  (2017) 17:598 Page 4 of 8
and DFS, but not for LRRFS or DMFS. Other prognostic
factors such as old age, current smoking, poor initial
performance status and advanced T stage were associ-
ated with inferior OS. For DFS, advanced N stage was an
additional significant prognostic factor. However, in
terms of LRRFS, patient age and use of induction
chemotherapy were not included in the Cox model. Age,
and T and N stage were also identified as independent
prognostic factors for DMFS.
Discussion
Controversy surrounds the treatment of tonsil cancer.
Both definitive surgery and radiotherapy resulted in
favorable outcomes in retrospective studies [5–7]. With
the use of chemotherapy, improved survival rates were
reported with both treatment modalities [9, 10]. How-
ever, no well-designed prospective study comparing
radiotherapy and surgery has been completed in the era
of widely used chemotherapy. The only prospective
Table 2 Univariate Analyses
Characteristic OS DFS LRRFS DMFS
No. 5Y (%) p-value No. 5Y (%) p-value No. 5Y (%) p-value No. 5Y (%) p-value
Sex
Male 523 80 0.082 521 73 0.037 525 86 0.025 522 91 0.787
Female 63 90 63 88 63 94 63 91
Age (years)
< 60 395 85 <0.001 393 80 <0.001 395 89 0.121 394 92 0.026
≥ 60 189 73 189 62 189 83 189 86
Smoking history
Never/ex-smoker 330 85 0.001 329 79 0.001 330 90 0.005 330 92 0.306
Current smoker 206 76 205 67 206 82 205 89
Performance status
ECOG 0 197 85 0.094 197 80 0.027 197 93 0.008 197 92 0.45
ECOG 1–2 372 79 370 72 372 85 371 90
PET/CT
No 182 79 0.226 181 74 0.847 182 88 0.669 182 93 0.311
Yes 404 83 403 74 404 87 403 89
T stage
T1–T2 426 87 <0.001 425 81 <0.001 426 90 0.003 425 94 <0.001
T3–T4 160 67 159 58 160 81 160 82
N stage
N0–N2b 504 84 0.005 503 78 <0.001 504 88 0.055 504 83 <0.001
N2c–N3 82 67 81 55 82 81 81 79
Stage
I–III 132 90 0.066 132 85 0.016 132 93 0.06 132 97 0.004
IVA–IVB 454 79 452 72 454 86 453 89
Chemotherapy
Concurrent/no 525 83 <0.001 523 76 0.006 525 88 0.263 524 90 0.762
Induction 61 71 61 64 61 83 61 93
Radiotherapy technique
3D–CRT 391 80 0.420 389 74 0.36 391 87 0.754 390 90 0.235
IMRT 194 84 194 76 194 88 194 92
Treatment modality
CRT 201 82 0.698 201 78 0.612 201 89 0.695 201 94 0.157
SRT 385 81 383 73 385 87 384 89
Abbreviations: OS overall survival, DFS disease-free survival, LRRFS locoregional recurrence-free survival, DMFS distant metastasis-free survival, ECOG Eastern
Cooperative Oncology Group, PET/CT positron emission tomography–computed tomography, 3D–CRT three-dimensional conformal radiotherapy, IMRT intensity
modulated radiotherapy, CRT radiotherapy with chemotherapy, SRT surgery followed by radiotherapy
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randomized trial comparing chemoradiotherapy and
surgery followed by radiotherapy was stopped prema-
turely due to slow accrual and therefore failed to detect
any significant difference in DFS between treatment
groups [13].
In the present study, we report the outcome of 586
patients from 16 hospitals. To the best of our know-
ledge, this is one of the largest tonsil cancer cohorts in
the literature. We found that old age and advanced T
stage which were associated with inferior survival in a
multivariate analysis are more found in the CRT group.
Despite these discrepancies in patient demographic and
disease stage, there was no significant difference between
the two treatment modalities under investigation in
terms of survival, recurrence, or failure pattern. Our
findings suggest that the CRT approach is more effective
than SRT; however, further studies are required to confirm
this hypothesis.
If the outcome is comparable between two treatment
options, morbidity associated with the treatment becomes
important when choosing the treatment modality. Unfor-
tunately, we were unable to collect extensive information
regarding treatment-related toxicities. Future trials should
address not only the outcomes of treatment, but also any
associated complications.
The outcomes of our multicenter study are compar-
able with those of previously published series. Canis et
al. reported the outcome of 102 tonsil cancer patients
Fig. 2 Overall survival according to presence or absence of induction chemotherapy in each treatment group
Table 3 Multivariate Analyses
OS DFS LRRFS DMFS
Characteristics p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI p-value HR 95% CI
Age (years)
≥ 60 <0.001 3.000 2.001–4.497 <0.001 2.516 1.779–3.560 0.009 2.227 1.217–4.077
Smoking history
Current smoker 0.012 1.663 1.116–2.478 0.015 1.54 1.089–2.176 0.014 1.919 1.141–3.226
Performance status
ECOG 1–2 0.045 1.566 1.010–2.426 0.017 1.587 1.087–2.315 0.019 2.094 1.130–3.879
T stage
T3–T4 <0.001 2.913 1.943–4.366 <0.001 2.572 1.808–3.659 0.021 1.852 1.097–3.127 <0.001 3.312 1.804–6.082
N stage
N2c–N3 0.069 1.542 0.966–2.462 0.008 1.735 1.155–2.607 0.075 1.747 0.946–3.226 0.007 2.435 1.271–4.664
Chemotherapy
Induction 0.003 2.224 1.313–3.768 0.033 1.712 1.044–2.806
Abbreviations: OS overall survival, DFS disease-free survival, LRRFS locoregional recurrence-free survival, DMFS distant metastasis-free survival, HR hazard ratio, CI
confidence interval, ECOG Eastern Cooperative Oncology Group
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who were treated with transoral laser microsurgery [14].
The 5-year locoregional control rates of T1–T2 and
T3–T4 stage tumors were 78 and 75%, respectively. In
the current study, the corresponding rates were 90 and
81%, respectively. Similarly, researchers from MD
Anderson Cancer Center reported 5-year locoregional
control and OS rates of 97 and 86%, respectively, in 120
patients who were treated with tonsillectomy followed
by postoperative radiotherapy [15]. Poulsen et al. studied
the outcomes of 148 patients who received surgery
followed by radiotherapy or definitive radiotherapy [16],
yielding 5-year locoregional control and OS rates of 84
and 57%, respectively. Other studies performed before the
early 2000s reported lower 5-year locoregional control
rates of 63–77% and OS rates of 53–60% [7, 17–19], pos-
sibly because these studies included a large proportion of
patients who were treated in the pre-chemotherapy era.
Although direct comparisons are not possible, our
treatment outcomes are acceptable when compared
with the literature.
In the present study, the induction chemotherapy
approach negatively influenced both OS and DFS, but had
little effect on LRRFS or DMFS in the multivariate ana-
lysis. These findings suggest that induction chemotherapy
may cause non-cancer related death. Recently, random-
ized trials reported increased toxicities and no survival
gain with induction chemotherapy [20, 21]. Despite the
limitations of retrospective studies (e.g., patient selection),
our findings support the proposal that the toxicity associ-
ated with routine use of induction chemotherapy
might be potentially harmful to tonsil cancer patients
who are highly curable without such treatment. This
is further indicated by our finding that patients with
tonsil cancer showed favorable prognosis and a low
rate of distant metastasis, despite 86% demonstrating
stage III–IVA disease.
Tobacco smoking is a well-known risk factor for head
and neck cancer [22]. Indian researchers reported that
prior tobacco abuse was an independent poor prognostic
factor for DFS and locoregional control in oropharyngeal
cancer [23]. Less than half of tumors in that study were
located in the tonsils. In our study, current smokers
showed significantly worse OS, DFS, and LRRFS than
non- or ex-smokers in the multivariate analysis. Differing
tumor biology in smokers may affect disease outcome
[24]. It is well known that persistent smoking during radi-
ation therapy adversely affects the response and survival
rate of head and neck cancer patients [25]. Smoking cessa-
tion may be beneficial and should be encouraged in
patients with tonsil cancer.
Age of >60 years was associated with a significant risk of
death, disease recurrence, and distant metastasis in the
multivariate analysis. HPV infection, which correlated
with favorable prognosis, was more frequently observed in
younger patients than in the elderly; [12] therefore,
smoking history and old age could be secondary surrogates
of poor tumor biology which is unrelated to HPV infection.
Unfortunately, because the HPV status of patients in the
present study was unknown, this hypothesis could not be
tested. Regarding that many recent studies for altering ther-
apy based on HPV status are in progress, the lack of details
of HPV status in this study has significant limitations [26].
Conclusion
Our large, multicenter, retrospective review of tonsil
cancer patients showed favorable survival and disease
control. Despite more high-risk patients being treated
with definitive chemoradiotherapy than surgery followed
by radiotherapy, demonstrated comparable outcomes.
Furthermore, our study indicated that induction chemo-
therapy is correlated with significant risk of death and
should not be routinely given to tonsil cancer patients.
Additional file
Additional file 1: Ethics information. (DOCX 13 kb)
Abbreviations
CRT: Chemoradiotherapy; CT: Computed tomography; DFS: Disease-free
survival; DMFS: Distant metastasis-free survival; ECOG: Eastern Cooperative
Oncology Group; HPV: Human papillomavirus; IMRT: Intensity modulated
radiotherapy; KROG: Korean Radiation Oncology Group; LRRFS: Locoregional
recurrence-free survival; OS: Overall survival; PET: Positron emission
tomography; SRT: Surgery followed by postoperative radiotherapy
Acknowledgements
None.
Funding
This research was supported by a grant from the National Research Foundation
of Korea (NRF), which is funded by the Korean government (MEST, grant
no.2015M2A2A7055063); a grant of the Korean Health Technology R&D Project,
Ministry of Health and Welfare, Republic of Korea (H14C3459); and the National
R&D Program through the Dong-nam Institute of Radiological and Medical
Sciences (DIRAMS) funded by the Ministry of Education, Science, and Technology
(50595–2016). The funding bodies had no role in the design of the study and
collection, analysis, and interpretation of data and in writing the manuscript.
Availability of data and materials
The datasets generated during and/or analysed during the current study are
available from the corresponding author on request.
Authors’ contributions
SS, HGW, LCG, KCK, YCA, DO, SWL, KHC, YSK, YTO and WTK were involved in
the study concept and design. Data acquisition was undertaken by CGL, KCK,
MSK, DO, HJP, SWL, GP, SHM, YW, YTO, WTK and JUJ. Analysis and
interpretation of data were performed by SS, HGW, YCA, YSK and KHC. SS,
HGW, HJP, GP, MSK, SHM, YW and JUJ drafted the manuscript. All of the
authors have read and approved the final manuscript.
Ethics approval and consent to participate
The study protocol was reviewed and approved by the Institutional Review
Boards of all participating hospitals, and adhered to the tenets of the Declaration
of Helsinki. Owing to retrospective approach of this study, the need for informed
consent was waived by the ethics committees. Additional information about the
ethics committees and waiver of informed consent is provided in Additional file 1.
Song et al. BMC Cancer  (2017) 17:598 Page 7 of 8
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Radiation Oncology, Kangwon National University Hospital,
Baengnyeong-ro 156, Chuncheon 24289, Republic of Korea. 2Department of
Radiation Oncology, Seoul National University College of Medicine, 101
Daehangno, Jongno-gu, Seoul 110-744, Republic of Korea. 3Department of
Radiation Oncology, Yonsei Cancer Center, 50-1 Yonsei-ro, Seodaemun-gu,
Seoul 03722, Republic of Korea. 4Department of Radiation Oncology,
Samsung Medical Center, Sungkyunkwan University School of Medicine, 81
Irwon-Ro Gangnam-gu, Seoul 06351, Republic of Korea. 5Department of
Radiation Oncology, Asan Medical Center, University of Ulsan College of
Medicine, Seoul, South Korea. 6Research Institute and Hospital, National
Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do 10408,
Republic of Korea. 7Department of Radiation Oncology, Seoul St. Mary’s
Hospital, The Catholic University of Korea, 222 Banpo-daero, Seocho-gu,
Seoul 06591, Republic of Korea. 8Department of Radiation Oncology, Ajou
University School of Medicine, Gyeonggi, South Korea. 9Department of
Radiation Oncology, Pusan National University Hospital and Pusan National
University School of Medicine, 179 Gudeok-ro, Seo-gu, Busan 49241, Republic
of Korea. 10Department of Radiation Oncology, Chonnam National University
Medical School, 42 Jebong-ro, Dong-gu, Gwangju 61469, Republic of Korea.
Received: 28 July 2016 Accepted: 21 August 2017
References
1. Cohan DM, Popat S, Kaplan SE, Rigual N, Loree T, Hicks WL Jr.
Oropharyngeal cancer: current understanding and management. Curr Opin
Otolaryngol Head Neck Surg. 2009;17:88–94.
2. Olaleye O, Moorthy R, Lyne O, Black M, Mitchell D, Wiseberg J. A 20-year
retrospective study of tonsil cancer incidence and survival trends in South
East England: 1987-2006. Clin Otolaryngol. 2011;36:325–35.
3. Mehta V, Yu GP, Schantz SP. Population-based analysis of oral and
oropharyngeal carcinoma: changing trends of histopathologic differentiation,
survival and patient demographics. Laryngoscope. 2010;120:2203–12.
4. Chung EJ, Oh JI, Choi KY, et al. Pattern of cervical lymph node metastasis in
tonsil cancer: predictive factor analysis of contralateral and retropharyngeal
lymph node metastasis. Oral Oncol. 2011;47:758–62.
5. Park G, Lee SW, Kim SY, et al. Can concurrent chemoradiotherapy replace
surgery and postoperative radiation for locally advanced stage III/IV tonsillar
squamous cell carcinoma? Anticancer Res. 2013;33:1237–43.
6. Koo TR, Wu HG, Hah JH, et al. Definitive radiotherapy versus postoperative
radiotherapy for tonsil cancer. Cancer Res Treat. 2012;44:227–34.
7. Mendenhall WM, Amdur RJ, Stringer SP, Villaret DB, Cassisi NJ. Radiation
therapy for squamous cell carcinoma of the tonsillar region: a preferred
alternative to surgery? J Clin Oncol. 2000;18:2219–25.
8. NCCN Guidelines Panels. NCCN clinical practice guidelines in oncology:
head and neck cancers. Available from URL: https://www.nccn.org/
professionals/physician_gls/pdf/head-and-neck.pdf. Accessed 29 Aug 2017.
9. Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy
versus concomitant chemotherapy and radiation therapy for advanced-
stage oropharynx carcinoma. J Natl Cancer Inst. 1999;91:2081–6.
10. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent
radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of
the head and neck. N Engl J Med. 2004;350:1937–44.
11. Ang KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of
patients with oropharyngeal cancer. N Engl J Med. 2010;363:24–35.
12. Westra WH. The changing face of head and neck cancer in the 21st century:
the impact of HPV on the epidemiology and pathology of oral cancer. Head
Neck Pathol. 2009;3:78–81.
13. Soo KC, Tan EH, Wee J, et al. Surgery and adjuvant radiotherapy vs concurrent
chemoradiotherapy in stage III/IV nonmetastatic squamous cell head and neck
cancer: a randomised comparison. Br J Cancer. 2005;93:279–86.
14. Canis M, Martin A, Kron M, et al. Results of transoral laser microsurgery in
102 patients with squamous cell carcinoma of the tonsil. Eur Arch
Otorhinolaryngol. 2013;270:2299–306.
15. Yildirim G, Morrison WH, Rosenthal DI, et al. Outcomes of patients with
tonsillar carcinoma treated with post-tonsillectomy radiation therapy. Head
Neck. 2010;32:473–80.
16. Poulsen M, Porceddu SV, Kingsley PA, Tripcony L, Coman W. Locally
advanced tonsillar squamous cell carcinoma: treatment approach revisited.
Laryngoscope. 2007;117:45–50.
17. Mendenhall WM, Morris CG, Amdur RJ, et al. Definitive radiotherapy for
tonsillar squamous cell carcinoma. Am J Clin Oncol. 2006;29:290–7.
18. Pernot M, Malissard L, Hoffstetter S, et al. Influence of tumoral,
radiobiological, and general factors on local-control and survival of a series
of 361 tumors of the velotonsillar area treated by exclusive irradiation
(external-beam irradiation plus brachytherapy or brachytherapy alone). Int J
Radiat Oncol Biol Phys. 1994;30:1051–7.
19. Perez CA, Patel MM, Chao KSC, et al. Carcinoma of the tonsillar fossa:
prognostic factors and long-term therapy outcome. Int J Radiat Oncol
BiolPhys. 1998;42:1077–84.
20. Haddad R, O'Neill A, Rabinowits G, et al. Induction chemotherapy followed by
concurrent chemoradiotherapy (sequential chemoradiotherapy) versus
concurrent chemoradiotherapy alone in locally advanced head and neck
cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol. 2013;14:257–64.
21. Cohen EEW, Karrison T, Kocherginsky M, et al. DeCIDE: a phase III
randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF)
induction chemotherapy (IC) in patients with N2/N3 locally advanced
squamous cell carcinoma of the head and neck (SCCHN). ASCO Meeting
Abstracts. 2012;30: 5500.
22. Marur S, Forastiere AA. Head and neck cancer: changing epidemiology,
diagnosis, and treatment. Mayo Clin Proc. 2008;83:489–501.
23. Agarwal JP, Mallick I, Bhutani R, et al. Prognostic factors in oropharyngeal
cancer–analysis of 627 cases receiving definitive radiotherapy. Acta Oncol.
2009;48:1026–33.
24. Ragin CC, Taioli E, Weissfeld JL, et al. 11q13 amplification status and human
papillomavirus in relation to p16 expression defines two distinct etiologies
of head and neck tumours. Br J Cancer. 2006;95:1432–8.
25. Browman GP, Wong G, Hodson I, et al. Influence of cigarette smoking on
the efficacy of radiation therapy in head and neck cancer. N Engl J Med.
1993;328(3):159–63.
26. Vokes EE, Agrawal N, Seiwert TY. HPV-associated head and neck cancer. J
Natl Cancer Inst. 2015;107(12):djv344.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Song et al. BMC Cancer  (2017) 17:598 Page 8 of 8
